Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsDNLI +5.63%33 Equity-to-Asset is 0.72 as of Jun. 2026, which is 8% below its 10-year median of 0.78. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Denali Therapeutics ranks better than 54.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Denali Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $835.18 Mil. Denali Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $1,157.96 Mil.
Therefore, Denali Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.72.
The historical rank and industry rank for Denali Therapeutics's Equity-to-Asset or its related term are showing as below:
DNLI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35 Med: 0.78 Max: 0.96
Current: 0.72
During the past 11 years, the highest Equity to Asset Ratio of Denali Therapeutics was 0.96. The lowest was -0.35. And the median was 0.78.
DNLI's Equity-to-Asset is ranked better than 54.94% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs DNLI: 0.72
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Denali Therapeutics Equity-to-Asset Related Terms
Denali Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DNLI vs RCUS, ALMS, ELVN: Equity-to-Asset Comparison
For the Biotechnology subindustry, Denali Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Denali Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (DNLI) has a Equity-to-Asset of 0.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Denali Therapeutics and its competitors. This is near median its historical median of 0.78. According to the industry distribution chart, Denali Therapeutics ranks #638 out of 1416 companies in the Biotechnology industry, placing it in the top 45.1%.
Is Denali Therapeutics' Equity-to-Asset too high?
Denali Therapeutics' current Equity-to-Asset of 0.72 is near median its 10-year median of 0.78. The Biotechnology industry median Equity-to-Asset is 0.68. Denali Therapeutics' value of 0.72 is 5.9% above this industry median. Based on the distribution chart, Denali Therapeutics ranks #638 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Equity-to-Asset compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #638 out of 1416 companies for Equity-to-Asset. This puts Denali Therapeutics in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Denali Therapeutics' value of 0.72 is 5.9% above this benchmark. While the company's 10-year median is 0.78 vs. the industry median of 0.68, Denali Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denali Therapeutics's current Equity-to-Asset of 0.72 is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Equity-to-Asset is 0.72, which is near median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Equity-to-Asset of 0.72. The current Equity-to-Asset is 0.72, which is near median its 10-year median of 0.78 and 5.9% above the Biotechnology industry median of 0.68. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Equity-to-Asset is 0.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score
Get the complete analysis for DNLI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNLI has been successfully added to your 
